Tasty Bite Eat. Q1 FY27 Results (NSE: TASTYBITE)
Signal: Margin pressure
The read
The key inflection is strong top-line recovery to ₹1,557.55 million, +28.6% YoY after the company-level fundamentals showed declining sales, but economics remain weaker: gross margin compressed 191bps to 38.6%, EBITDA grew only 4.4%, and 49.4% of PBT came from other income, leaving the quality of the operating recovery unproven.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹155.76 Cr | 28.6% | 32.4% |
| EBIT | ₹12.88 Cr | 4.8% | |
| Net profit | ₹8.84 Cr | 7.9% | |
| EPS | ₹34.45 | 8.0% | |
| EBIT margin | 13.3% |
P&L walk
Revenue increased to ₹1,557.55 million, +28.6% YoY and +32.4% QoQ, but gross margin fell to 38.6% from 40.5% as total material and inventory costs rose faster than sales; EBITDA margin was 13.3% and PAT rose 7.9%, with other income equal to 49.4% of PBT.
Key positives
- Revenue from operations reached ₹1,557.55 million, +28.6% YoY and +32.4% QoQ, indicating a sharp sequential recovery.
- Raw material cost as a percentage of revenue fell to 64.6% from 70.0% YoY, while revenue grew 28.6% versus cost of materials growth of 18.6%, suggesting some pass-through despite gross-margin compression.
- Finance costs declined 22.4% YoY to ₹9.66 million, reducing pressure below EBITDA.
- EPS rose 8.0% YoY to ₹34.45 and tracked PAT growth of 7.9%.
Key concerns
- Gross margin declined approximately 191bps YoY to 38.6%, with total material and inventory costs rising to ₹957.17 million from ₹721.11 million; the filing does not disclose the cause.
- EBITDA grew only 4.4% YoY to ₹20.66 crore against 28.6% revenue growth, indicating weak conversion of sales growth into operating profit.
- Employee benefits plus other expenses increased 35.8% YoY to ₹452.59 million, faster than revenue growth of 28.6%.
- PAT growth of 7.9% was far below revenue growth and was materially influenced by other income of ₹58.85 million, equal to 49.4% of PBT.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.